Bioscan Research Raises $1 Million in Seed Funding
Bioscan Research, a medtech startup specializing in advanced neurological scans for the detection and treatment of traumatic intracerebral and intracranial hemorrhage, has raised $1 million in a seed funding round. The round was led by Unicorn India Ventures, a prominent investor in innovative healthcare technologies.
Founded in 2017, Bioscan Research aims to improve outcomes for patients with traumatic brain injuries through early detection and treatment. Their flagship product, CEREBO, utilizes machine learning and near-infrared spectroscopy (NIRS) to identify intra-cranial injuries even in the absence of visible symptoms.
Strategic Use of Funds
The $1 million raised will be strategically deployed to support several key initiatives. These include expanding market reach, obtaining additional regulatory approvals, upgrading existing products, and developing new intellectual property. The company is dedicated to enhancing its technology to bridge the gaps left by traditional diagnostic tools.
Market Potential and Need
The need for advanced brain injury diagnostics is pressing, with over 50 million individuals affected by traumatic brain injuries each year globally. Many cases go undiagnosed, particularly mild traumatic injuries, which can have significant long-term impacts if not properly identified and managed. By improving detection capabilities, Bioscan Research seeks to provide critical support in urgent care settings both in India and internationally.
Investor Insights
Anil Joshi, Managing Partner at Unicorn India Ventures, expressed the investment firm's confidence in the medtech sector's potential. "We believe the healthcare industry still has a big gap to address in countries like India," Joshi noted, highlighting the significant market opportunity for innovative solutions like those developed by Bioscan Research.
This funding round marks an important milestone for Bioscan Research as it continues to innovate in the field of neurological diagnostics, aiming to enhance patient care and outcomes through cutting-edge technology.